|By PR Newswire||
|April 25, 2014 09:00 AM EDT||
ROCKLAND, Mass., April 25, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.
Data from 14 study assessments presented by EMD Serono or its affiliate, Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, will focus on Rebif® (interferon beta-1a), as well as three pipeline candidates:
- Ceralifimod (ONO-4641) (S1P receptor agonist), an investigational oral compound being evaluated in a Phase II trial for relapsing-remitting MS.
- ATX MS-1467, an investigational compound being evaluated in a Phase I trial for MS.
- Plovamer Acetate (PI-2301), a second-generation peptide copolymer being evaluated in a Phase II clinical trial for MS. Plovamer Acetate is designed to bind to major histocompatibility complex (MHC) class II allelic variants associated with MS, with the aim of promoting regulatory effects in the immune system.
"The data to be presented during the AAN meeting continue to advance our understanding of the important clinical effects of Rebif and demonstrate progress with our three pipeline candidates," said Thorsten Eickenhorst, Chief Medical Officer, EMD Serono. "Our company's scientific commitment to MS includes more than 20 years of clinical experience with Rebif and we continue to work to develop innovative treatment options and solutions for those living with MS."
The following abstracts have been accepted for presentation at the 66th AAN Annual Meeting:
Rebif (interferon beta-1a)
- Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a (Poster P3.146 Session III; Tuesday, April 29, 2014)
- Correlations between Immunological Biomarkers and Conventional and Advanced MRI Measures Following Interferon Beta-1a Treatment for Relapsing-Remitting Multiple Sclerosis (Poster P3.147 Session III; Tuesday, April 29, 2014)
- Early and Consistent Reduction in Relapses among Patients with Relapsing-Remitting Multiple Sclerosis Receiving Subcutaneous Interferon Beta-1a: A Post-Hoc Analysis of PRISMS Data (Poster P3.182 Session III; Tuesday, April 29, 2014)
- Assessing a Scoring System to Predict Disease Activity in Patients with Multiple Sclerosis: Post Hoc Analyses of Data from Clinical Trials of Subcutaneous Interferon Beta-1a (Poster P3.178 Session III; Tuesday, April 29, 2014)
- Changes in Immunological Biomarkers in Patients with Relapsing–Remitting Multiple Sclerosis Treated with Interferon Beta-1a (Poster P4.132 Session IV; Wednesday, April 30, 2014)
- Associations Between Changes in Ferritin Levels and Susceptibility-Weighted Imaging Filtered Phase in Patients with Relapsing-Remitting Multiple Sclerosis over Six Months Therapy with Interferon Beta-1a (Poster P6.115, Session VI; Thursday, May 1, 2014)
- Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240, Session VII; Thursday, May 1, 2014)
- Adherence to, and Effectiveness of, Treatment with Subcutaneous Interferon Beta-1a in Relapsing Multiple Sclerosis Patients using RebiSmart™ for Self-Injection: Final Results of the One-Year International, Observational SMART Study (P7.219, Session VII; Thursday, May 1, 2014)
- Ceralifimod (ONO-4641) Reduces MRI Lesions and Prevents Disease Progression in an Animal Model of Multiple Sclerosis (P1.219, Session I; Monday, April 28, 2014)
- Ceralifimod (ONO-4641) Prevents Evoked Potential Deficits in an Animal Model of Multiple Sclerosis (P1.218, Session I; Monday, April 28, 2014)
- Effect of Ceralifimod (ONO-4641), a Sphingosine-1-Phosphate Receptor-1 and -5 Agonist, on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Interim Results from the Extension of the DreaMS Study (P3.161, Session III; Tuesday, April 29, 2014)
- ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216, Session I, Monday, April 28, 2014)
- Preclinical Efficacy and Phase I Clinical Testing of ATX-MS1467, an Antigen-Specific Immunotherapy for Multiple Sclerosis (P1.189, Session I; Monday, April 28, 2014)
Plovamer Acetate (PI-2301)
- Differentiating Plovamer Acetate and Glatiramer Acetate: Efficacy and Mechanism of Action in a Preclinical Model of Multiple Sclerosis (P1.187, Session I; Monday, April 28, 2014)
EMD Serono is engaged in strategic research collaborations funding promising neurology research with leading academic and healthcare institutions. Learn more about EMD Serono's programs, pipeline and activities in neurology by visiting booths #1133 and #1332 at this year's AAN Annual Meeting.
About Rebif® (interferon beta-1a)
Rebif is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. Rebif is not approved for treatment of chronic progressive MS. Rebif is available in 22 mcg and 44 mcg prefilled, preassembled syringes and a titration pack.
Rebif will not cure MS but it has been shown to decrease the number of flare-ups and slow the occurrence of some of the physical disability that is common in people with MS. Rebif can cause serious side effects, so before taking Rebif, patients should talk with their doctor about the possible benefits of Rebif and its possible side effects.
Potential serious side effects of Rebif include depression, liver problems, risk to pregnancy, allergic reactions and injection-site problems. Patients who have had an allergic reaction such as difficulty breathing, flushing or hives to another interferon beta or to human albumin should not take Rebif.
Before taking Rebif (interferon beta-1a), patients should tell their doctor if they have a history of depression, anxiety, trouble sleeping, liver disease, thyroid problems, blood cell count or bleeding problems, epilepsy, or are planning to become pregnant. Patients should tell their doctor about all medicines they take, including prescription and non-prescription medicines, vitamins and herbal supplements. Rebif and other medicines may affect each other causing serious side effects. Patients should talk to their doctor before taking any new medicines.
Possible side effects of Rebif include flu-like symptoms (fever, chills, sweating, muscle aches and tiredness), injection-site reactions, depression and anxiety, liver problems, abdominal pain, blood problems, thyroid problems and severe allergic reactions. Patients should let their doctor know if they have any of these symptoms or feel sad, tired, hot or cold, or experience hives, rashes, bruising, yellowing of the skin, or a change in body weight (gain or loss).
This information is not intended to replace discussions with a doctor. For additional information about Rebif, please consult the Prescribing Information and Medication Guide at www.rebif.com and talk to a health care professional. Information is also available at www.mslifelines.com or call toll-free 1-877-44-REBIF (1-877-447-3243). Rebif is available by prescription only.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a specialized biopharmaceutical company dedicated to developing therapies with groundbreaking potential. The company has strong market positions in neurology, endocrinology and in reproductive health. In addition, EMD Serono has an enduring commitment to solve the unsolvable, with state-of-the-art science dedicated to developing new therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology. With a long-standing history of industry expertise and a dedication to shape the future of healthcare, the company's US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. Its subsidiaries in Canada and the United States operate under the umbrella brand EMD. Around 38,000 employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. The company generated total revenues of €11.1 billion in 2013 with its four divisions: Biopharmaceuticals, Consumer Health, Performance Materials and Life Science Tools. Merck KGaA of Darmstadt, Germany is the world's oldest pharmaceutical and chemical company – since 1668, the name has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day.
SOURCE EMD Serono
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, shared some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, de...
May. 28, 2015 04:00 AM EDT Reads: 6,320
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. ...
May. 28, 2015 04:00 AM EDT Reads: 6,685
Grow your business with enterprise wearable apps using SAP Platforms and Google Glass. SAP and Google just launched the SAP and Google Glass Challenge, an opportunity for you to innovate and develop the best Enterprise Wearable App using SAP Platforms and Google Glass and gain valuable market exposure. In his session at @ThingsExpo, Brian McPhail, Senior Director of Business Development, ISVs & Digital Commerce at SAP, outlined the timeline of the SAP Google Glass Challenge and the opportunity...
May. 28, 2015 03:00 AM EDT Reads: 4,989
As enterprises look to take advantage of the cloud, they need to understand the importance of safeguarding their confidential and sensitive data in cloud environments. Enterprises must protect their data from (i) system administrators who don't need to see the data in the clear and (ii) adversaries who become system administrators from stolen credentials. In short, enterprises must take control of their data: The best way to do this is by using advanced encryption, centralized key management and...
May. 28, 2015 02:00 AM EDT Reads: 4,439
What are the benefits of using an enterprise-grade orchestration platform? In their session at 15th Cloud Expo, Nate Gordon, Director of Technology at Appcore, and Kedar Poduri, Senior Director of Product Management at Citrix Systems, took a closer look at the architectural design factors needed to support diverse workloads and how to run these workloads efficiently as a service provider. They also discussed how to deploy private cloud environments in 15 minutes or less.
May. 28, 2015 01:00 AM EDT Reads: 3,581
In his session at DevOps Summit, Andrei Yurkevich, CTO at Altoros, provided an overview of all the benefits and opportunities, as well as drawbacks of deploying Cloud Foundry PaaS with Juju and compared it to BOSH. Discover the features that overlap, and understand what Juju Charm is, what it is not, where you use one or the other or where you use both BOSH and Juju Charms together. Andrei Yurkevich is Cloud Foundry protagonist and CTO at Altoros. Under his supervision, the Altoros engineering ...
May. 28, 2015 12:00 AM EDT Reads: 4,542
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water,...
May. 27, 2015 11:00 PM EDT Reads: 6,009
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrateg...
May. 27, 2015 10:00 PM EDT Reads: 5,391
For better or worse, DevOps has gone mainstream. All doubt was removed when IBM and HP threw up their respective DevOps microsites. Where are we on the hype cycle? It's hard to say for sure but there's a feeling we're heading for the "Peak of Inflated Expectations." What does this mean for the enterprise? Should they avoid DevOps? Definitely not. Should they be cautious though? Absolutely. The truth is that DevOps and the enterprise are at best strange bedfellows. The movement has its roots in t...
May. 27, 2015 10:00 PM EDT Reads: 6,292
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of...
May. 27, 2015 09:00 PM EDT Reads: 6,408
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impac...
May. 27, 2015 09:00 PM EDT Reads: 4,898
One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences. In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, described an IoT-specific approach to user experience design that combines approaches from interaction design, industrial design and service design to create experiences that go beyond simple connected gadgets to create lasting, multi-device exp...
May. 27, 2015 09:00 PM EDT Reads: 6,008
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. 8th International Big Data Expo, co-located with 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. As advanced data storage, access and analytics technologies aimed at handling high-volume and/or fast moving data all move center stage, aided by the cloud computing bo...
May. 27, 2015 08:45 PM EDT Reads: 1,483
Containers Expo Blog covers the world of containers, as this lightweight alternative to virtual machines enables developers to work with identical dev environments and stacks. Containers Expo Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. Bookmark Containers Expo Blog ▸ Here Follow new article posts on Twitter at @ContainersExpo
May. 27, 2015 08:00 PM EDT Reads: 1,113
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
May. 27, 2015 08:00 PM EDT Reads: 4,802